Navigate Up
Sign In


As a signatory to Switzerland’s Pharma Cooperation Code (PCC) and starting in 2016, MSD will disclose annually the transfers of value provided to healthcare professionals and organisations in the prior year.MSD supports the PCC and the efforts to increase transparency and thus strengthen the trust in interactions and collaboration between the pharmaceutical industry and healthcare providers. The overview of the transfers of value provided by MSD in 2015 is available here.

For more than 25 years MSD has been successfully fighting against river blindness through the Mectizan Donation Program (MDP), the longest drug donation initiative in the world. MSD has committed itself to supplying Mectizan free of charge in sufficient quantities and for long enough until river blindness is eliminated worldwide. For the development of the drug Mectizan (ivermectin) the former MSD employee William C. Campbell received the 2015 Nobel Prize in Medicine.
Read more.

“20 years of the KVG (Swiss Federal Health Insurance Act): Where from – where to?” discussed at the 12th “Trendtage Gesundheit Luzern” (Health Trend Days) Event.
Read more.

​MSD in Switzerland

MSD is one of the world's leading healthcare companies, with its headquarters in the USA (Merck & Co., Inc., Kenilworth, NJ, USA). In Switzerland, MSD is one of the most important pharmaceutical research companies. From our base at Lucerne we serve the Swiss healthcare market and support more than 70 subsidiaries across Europe, Canada, the Middle East, Africa, Brazil, India, and China. Welcome to MSD.

MSD as an employer 
To achieve our ambitious goals, we need the best possible specialist staff and highly committed employees. We offer various positions in a wide range of business areas like for example within our local and international sales organizations, research & development, manufacturing, and within the core departments of our global business located in Lucerne.
Find out more​

​The Antibiotics Challenge  

For more than 70 years, MSD has contributed to the discovery and development of novel medicines to combat infectious diseases. The combination with the bio-pharmaceutical company Cubist in January 2015 is an important milestone in this respect to intensify research in view of an increasing resistance against antibiotics – one of the biggest global health challenges - and develop innovative medicines for patients with potentially life-threatening infections diseases caused by bacteria. Cubist’s deep expertise and compelling portfolio and pipeline complement our broad portfolio of Hospital Acute Care. This will help advance a pipeline of candidates that hold the potential for making a meaningful difference in the lives of patients around the world.

General Remark:
Please be aware of the fact that each time when using one of the links in this website, you are leaving the Merck Sharp & Dohme AG, Switzerland (MSD), website and thus our sphere of responsibility. The linked Internet pages have their own terms of use and may be subject to different laws and standards.